Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Clinical trial NCT07198074 · RECRUITING
Trial details
- NCT number
- NCT07198074
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-27
- Primary completion
- 2028-07-01
- Enrollment
- 255
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.